BioSpace News Archive

Calyxt, Inc. announced that it has signed an agreement with its first manufacturing partner, Evologic Technologies GmbH, to further develop and scale Calyxt’s proprietary Plant Cell Matrix™ technology platform.

Evogene Ltd. announced today that Ofer Haviv , Evogene’s President and CEO, will attend and present at LD Micro Main Event taking place from Tuesday, October 25 to Wednesday, October 26, 2022, in Los Angeles.

EpicentRx announced today the start of dosing in China for the global Phase 3 clinical trial REPLATINUM (NCT05566041) with partner SciClone Pharmaceuticals.

Dipharma Francis S.r.l. announced that the Italian Medicines Agency approved the brand-new production line at the cGMP pilot plant suite, located in its facility of Mereto di Tomba.

West Pharmaceutical Services, Inc. announced it has been shortlisted for Company of the Year for 2022 Global Generics and Biosimilar Awards, which will be announced during CPhI Worldwide in Frankfurt, Germany on November 2, 2022.

Sensorion is pleased to announce Sensorion’s participation in two scientific conferences in October 2022.

AlzeCure Pharma announced that the company is participating at Redeye Theme: Neurology on October 12, where CEO Martin Jönsson will present the company’s latest developments.

Centogene N.V., the commercial-stage essential biodata life science partner for rare and neurodegenerative diseases, announced its partnering conference schedule for October 2022.

ViewRay, Inc. announced that SUNY Upstate Cancer Center in Syracuse, New York has selected MRIdian MRI-Guided Radiation Therapy System and will be the first in Upstate New York to offer the precision of MRIdian’s advanced MRI-guided radiation therapy to cancer patients throughout the region for pancreas, prostate, lung, liver, breast, and oligometastatic cancers.

Nuvalent, Inc., a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, announced the appointment of Michael L. Meyers, M.D., Ph.D., to its Board of Directors.